Boston Scientific Corporation (BSX) Rated as a ‘Buy’ at Needham on IVL Market Opportunity

Group 1 - Boston Scientific Corporation (BSX) is viewed positively by analysts, with a 'Buy' rating and a price target of $121, as the company prepares to launch its Bolt laser-based intravascular lithotripsy (IVL) system for peripheral use in late 2025 [1][2] - The company is currently enrolling participants for a fracture study to assess the clinical application of the IVL technology, targeting an $8.5 billion market opportunity [2][3] - The Bolt system is expected to outperform Shockwave Medical's IVL system in terms of deliverability, pulse count, and reliability, which should facilitate rapid market share acquisition in the IVL segment [3] Group 2 - The IVL technology is projected to contribute an additional 0.3% to Boston Scientific's revenue growth and 0.5% to earnings per share (EPS) growth over the next five years [3] - Boston Scientific is a global medical technology company focused on developing and selling less-invasive medical devices aimed at improving patient outcomes and reducing healthcare costs [4]